Evolus Provides Update on International Trade Commission (ITC) Case
“In several media reports this week, Medytox has made comments on the
Importantly, nothing has changed as a result of the media reports from
The ITC Judge will make his own independent decision based upon all the evidence presented at the hearing and through all of the parties’ filings. The Judge assigned to the ITC case is not obligated to accept a staff attorney’s position on the facts, and it’s fairly common for the Judge and the staff attorney to disagree on substantive matters.
In addition, numerous claims have been made in the Korean press regarding settlement discussions related to the ITC proceedings. It is the company’s policy to not confirm or comment on settlement discussions.”
Prior to the ITC hearings held
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: www.evolus.com.
Jeuveau® is a registered trademark of
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Vice President, Finance, Investor Relations &
This statement contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements that relate to the status of regulatory processes, future plans, events, prospects or performance and statements containing the words “plans,” “expects,” “believes,” “strategy,” “opportunity,” “anticipates,” “outlook,” “designed,” or other forms of these words or similar expressions, although not all forward-looking statements contain these identifying words. The company’s forward-looking statements include, but are not limited to, statements related to the strength of our intellectual property and the status and outlook of ongoing litigation.
Forward-looking statements are based on current estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Other factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with the success of the launch of Jeuveau®, customer and consumer adoption of the product, competition and market dynamics, our ongoing legal proceedings and our ability to maintain regulatory approval of Jeuveau® and other risks described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended